James Mu

James Mu

Auto-generated profile, based on publicly available information

James Mu

Merck & Co., Inc., South San Francisco, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2001 in Science
Verified
Journal Article
Closed access
PDF file
HCHan Cho
Han Cho
JMJames Mu
James Mu
JKJason K. Kim
Jason K. Kim
JTJoanne L. Thorvaldsen
Joanne L. Thorvaldsen
QCQingwei Chu
Qingwei Chu
MBMorris J. Birnbaum
Morris J. Birnbaum
Glucose homeostasis depends on insulin responsiveness in target tissues, most importantly, muscle and liver. The critical initial steps in insulin action include phosphorylation of scaffolding proteins and activation of phosphatidylinositol 3-kinase. These early events lead to activation of the serine-threonine protein kinase Akt, also known as protein kinase B. We show that mice deficient in Akt2 are impaired in the ability of insulin to lower blood glucose because of defects in the action of the hormone on liver and skeletal muscle. These data establish Akt2 as an essential gene in the maintenance of normal glucose homeostasis.

1 April 2005 in Molecular Cell
Verified
Journal Article
Closed access
RJRussell G. Jones
Russell G. Jones
DPDavid R. Plas
David R. Plas
SKSara Kubek
Sara Kubek
MBMonica Buzzai
Monica Buzzai
JMJames Mu
James Mu
CTCraig B. Thompson
Craig B. Thompson

17 March 2004 in Nature
Verified
Journal Article
Closed access
PDF file
YMYasuhiko Minokoshi
Yasuhiko Minokoshi
TAThierry Alquier
Thierry Alquier
NFNoboru Furukawa
Noboru Furukawa
YKYoung-Bum Kim
Young-Bum Kim
ALAnna Lee
Anna Lee
BKBarbara B. Kahn
Barbara B. Kahn

20 November 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
HZHaihong Zong
Haihong Zong
JRJian Ming Ren
Jian Ming Ren
LYLawrence H. Young
Lawrence H. Young
MPMarc Pypaert
Marc Pypaert
JMJames Mu
James Mu
GSGerald I. Shulman
Gerald I. Shulman
Mitochondrial biogenesis is a critical adaptation to chronic energy deprivation, yet the signaling mechanisms responsible for this response are poorly understood. To examine the role of AMP-activated protein kinase (AMPK), an evolutionarily conserved fuel sensor, in mitochondrial biogenesis we studied transgenic mice expressing a dominant-negative mutant of AMPK in muscle (DN-AMPK). Both DN-AMPK and WT mice were treated with β-guanidinopropionic acid (GPA), a creatine analog, which led to similar reductions in the intramuscular ATP/AMP ratio and phosphocreatine concentrations. In WT mice, GPA treatment resulted in activation of muscle AMPK and mitochondrial biogenesis. However, the same GPA treatment in DN-AMPK mice had no effect on AMPK activity or mitochondrial content. Furthermore, AMPK inactivation abrogated GPA-induced increases in the expression of peroxisome proliferator-activated receptor γ coactivator 1α and calcium/calmodulin-dependent protein kinase IV (both master regulators of mitochondrial biogenesis). These data demonstrate that by sensing the energy status of the muscle cell, AMPK is a critical regulator involved in initiating mitochondrial biogenesis.

1 May 2001 in Molecular Cell
Verified
Journal Article
Closed access
JMJames Mu
James Mu
JBJoseph T Brozinick
Joseph T Brozinick
OVOtto Valladares
Otto Valladares
MBMaja Bucan
Maja Bucan
MBMorris J Birnbaum
Morris J Birnbaum

1 June 2006 in Diabetes
Verified
Journal Article
Open access
PDF file
JMJames Mu
James Mu
JWJohn Woods
John Woods
YZYun-Ping Zhou
Yun-Ping Zhou
RRRanabir Sinha Roy
Ranabir Sinha Roy
ZLZhihua Li
Zhihua Li
BZBei B. Zhang
Bei B. Zhang
Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of incretin hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major unanswered question concerns the potential ability of DPP-4 inhibition to have beneficial disease-modifying effects, specifically to attenuate loss of pancreatic β-cell mass and function. Here, we investigated the effects of a potent and selective DPP-4 inhibitor, an analog of sitagliptin (des-fluoro-sitagliptin), on glycemic control and pancreatic β-cell mass and function in a mouse model with defects in insulin sensitivity and secretion, namely high-fat diet (HFD) streptozotocin (STZ)-induced diabetic mice. Significant and dose-dependent correction of postprandial and fasting hyperglycemia, HbA1c, and plasma triglyceride and free fatty acid levels were observed in HFD/STZ mice following 2–3 months of chronic therapy. Treatment with des-fluoro-sitagliptin dose dependently increased the number of insulin-positive β-cells in islets, leading to the normalization of β-cell mass and β-cell–to–α-cell ratio. In addition, treatment of mice with des-fluoro-sitagliptin, but not glipizide, significantly increased islet insulin content and improved glucose-stimulated insulin secretion in isolated islets. These findings suggest that DPP-4 inhibitors may offer long-lasting efficacy in the treatment of type 2 diabetes by modifying the courses of the disease.